THE PAST 12 MONTHS
- Building off our successful $5million raise at the end of 2017, we completed an RTO to enable trading on the CSE under the symbol :PILL.
- Along with our Canadian licensing partner, Emblem, we have received Health Canada approval for R&D of our innovative oral sustained release formulation of cannabinoids.
- We have increased our IP protection, bringing our patent applications up to 13, along with our 10 trademark applications in the US and Canada.
- We have received a Health Canada Natural Products Number to market our Hemp Oil Capsules, which will be marketed under our new wellness brand, 420 Therapeutics.
- We have signed a joint venture to distribute our Extended Release Tablets in Australia and are negotiating deals in other markets such as Germany.
- We are working to set up a GMP manufacturing line in Coburg, Ontario for domestic and international product.
- We are working with a group in Jamaica to import raw product and export finished product for the Caribbean market.
CAPITALIZED FOR GROWTH
• We have a clear vision to become a leader in oral dosage cannabis, with unique products that offer advantages to the medical community, patients, adult use consumers and governments.
• Clear and Sustainable Competitive Advantage Through Robust Intellectual Property with 13 patents pending.
• Well financed, publicly traded on the CSE (:PILL).
• We’ve created valuable licensing and joint venture deals in Canada and international markets, such as Australia and Germany.
• We’re launching our first two products under the 420 Therapeutics brand in the coming months.
• Along with our Canadian licensing partner, Emblem, we’ve received Health Canada approval for the development and clinical trials of our breakthrough Extended Release (XR) Tablets.
• Robust new product development, including the development of 420 Therapeutics, with the goal to be a leader in the wellness category.
• Established Leadership with a Track Record of Driving Value.
Interested in what we do? Want to learn more about the opportunities we offer? Get in touch, enter your information and ask any questions you may have. We'll be sure to respond as soon as possible.
Sign up for our monthly newsletter and keep up to date.
Copyright Canntab Therapeutics, 2018 ©